Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Diabetic Macular Edema
Biotech
Oxurion fails phase 2 eye disease trial, plans bankruptcy filing
The last program standing in what was once a three-front attack on eye diseases failed, prompting Oxurion to start preparing to file for bankruptcy.
Nick Paul Taylor
Nov 20, 2023 8:30am
Kodiak resurrects eye drug after ph. 3 data renew approval plans
Nov 6, 2023 8:40am
'Unexpected' cataracts in ph. 3 end Kodiak's hopes for eye drug
Jul 24, 2023 8:58am
Unity preps for Eylea battle following extended midstage test
Apr 24, 2023 10:25am
Unity's ophthalmology asset improves vision in phase 2
Nov 1, 2022 11:10am
Digital Diagnostics dials up $75M for diabetic retinopathy AI
Aug 23, 2022 7:30am